LIFECORE BIOMEDICAL, INC. \DE\ — Financial Data
Annual figures from SEC EDGAR XBRL filings (10-K)
These figures are extracted directly from XBRL-tagged financial statements that LIFECORE BIOMEDICAL, INC. \DE\ filed with the SEC as part of its annual 10-K reports. XBRL (eXtensible Business Reporting Language) is a structured data format the SEC requires for machine-readable financial disclosures. Values shown are as reported — negative figures indicate a loss and are shown in red.
Revenue
Total revenue from all business activities — the top line of the income statement. Represents all money earned before any expenses are deducted.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2019 | May 26, 2019 | $152.78M | Aug 1, 2019 |
| FY2019 | Feb 24, 2019 | $155.55M | Aug 1, 2019 |
| FY2019 | Nov 25, 2018 | $124.56M | Aug 1, 2019 |
| FY2019 | Aug 26, 2018 | $124.67M | Aug 1, 2019 |
| FY2019 | May 27, 2018 | $141.08M | Aug 1, 2019 |
| FY2019 | Feb 25, 2018 | $144.91M | Aug 1, 2019 |
| FY2019 | Nov 26, 2017 | $122.46M | Aug 1, 2019 |
| FY2019 | Aug 27, 2017 | $115.78M | Aug 1, 2019 |
| FY2018 | May 28, 2017 | $121.27M | Aug 9, 2018 |
| FY2018 | Feb 26, 2017 | $129.29M | Aug 9, 2018 |
Revenue (Net Sales)
Net sales revenue — gross revenue less returns, allowances, and discounts. Used by many manufacturers and retailers as the primary top-line figure.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2017 | May 28, 2017 | $532.26M | Mar 15, 2018 |
| FY2017 | May 29, 2016 | $541.10M | Mar 15, 2018 |
| FY2017 | May 31, 2015 | $539.26M | Mar 15, 2018 |
| FY2016 | May 25, 2014 | $476.81M | Aug 1, 2016 |
| FY2015 | May 26, 2013 | $441.71M | Jul 31, 2015 |
| FY2014 | May 27, 2012 | $317.55M | Aug 1, 2014 |
Gross Profit
Revenue minus the cost of goods sold (COGS). Gross profit shows how much revenue remains to cover operating expenses, R&D, and administrative costs before calculating operating income.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | May 25, 2025 | $40.30M | Aug 7, 2025 |
| FY2025 | May 26, 2024 | $41.85M | Aug 7, 2025 |
| FY2023 | May 28, 2023 | $7.78M | Mar 20, 2024 |
| FY2023 | Feb 26, 2023 | $8.55M | Mar 20, 2024 |
| FY2023 | Nov 27, 2022 | $5.68M | Mar 20, 2024 |
| FY2023 | Aug 28, 2022 | $5.98M | Mar 20, 2024 |
| FY2023 | May 29, 2022 | $10.42M | Mar 20, 2024 |
| FY2023 | Feb 27, 2022 | $11.64M | Mar 20, 2024 |
| FY2023 | Nov 28, 2021 | $11.46M | Mar 20, 2024 |
| FY2023 | Aug 29, 2021 | $5.55M | Mar 20, 2024 |
Net Income
The bottom-line profit — what remains after all operating expenses, interest, taxes, and other costs are deducted. A negative value means the company reported a net loss for the year.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | May 25, 2025 | ($38.72M) | Aug 7, 2025 |
| FY2025 | May 26, 2024 | $12.01M | Aug 7, 2025 |
| FY2024 | May 28, 2023 | ($99.56M) | Aug 26, 2024 |
| FY2023 | Feb 26, 2023 | ($36.51M) | Mar 20, 2024 |
| FY2023 | Nov 27, 2022 | ($12.81M) | Mar 20, 2024 |
| FY2023 | Aug 28, 2022 | ($10.97M) | Mar 20, 2024 |
| FY2024 | May 29, 2022 | ($116.72M) | Aug 26, 2024 |
| FY2023 | Feb 27, 2022 | ($13.59M) | Mar 20, 2024 |
| FY2023 | Nov 28, 2021 | ($38.47M) | Mar 20, 2024 |
| FY2023 | Aug 29, 2021 | ($9.39M) | Mar 20, 2024 |
Operating Income
Profit from core business operations before interest expense and income taxes (also known as EBIT). Excludes non-operating items, making it a cleaner measure of operational efficiency than net income.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | May 25, 2025 | ($17.25M) | Aug 7, 2025 |
| FY2025 | May 26, 2024 | ($8.84M) | Aug 7, 2025 |
| FY2024 | May 28, 2023 | ($21.80M) | Aug 26, 2024 |
| FY2023 | Feb 26, 2023 | ($6.53M) | Mar 20, 2024 |
| FY2023 | Nov 27, 2022 | ($5.35M) | Mar 20, 2024 |
| FY2023 | Aug 28, 2022 | ($3.27M) | Mar 20, 2024 |
| FY2024 | May 29, 2022 | ($11.79M) | Aug 26, 2024 |
| FY2023 | Feb 27, 2022 | ($9.64M) | Mar 20, 2024 |
| FY2023 | Nov 28, 2021 | $3.69M | Mar 20, 2024 |
| FY2023 | Aug 29, 2021 | ($4.22M) | Mar 20, 2024 |
R&D Expense
Spending on research and development activities — developing new products, improving existing ones, or conducting basic research. High R&D relative to revenue is common in technology and pharmaceutical companies.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | May 25, 2025 | $8.26M | Aug 7, 2025 |
| FY2025 | May 26, 2024 | $8.58M | Aug 7, 2025 |
| FY2024 | May 28, 2023 | $8.74M | Aug 26, 2024 |
| FY2023 | Feb 26, 2023 | $2.23M | Mar 20, 2024 |
| FY2023 | Nov 27, 2022 | $2.18M | Mar 20, 2024 |
| FY2023 | Aug 28, 2022 | $2.21M | Mar 20, 2024 |
| FY2024 | May 29, 2022 | $7.84M | Aug 26, 2024 |
| FY2023 | Feb 27, 2022 | $2.25M | Mar 20, 2024 |
| FY2023 | Nov 28, 2021 | $1.68M | Mar 20, 2024 |
| FY2023 | Aug 29, 2021 | $1.69M | Mar 20, 2024 |
SG&A Expense
Selling, general, and administrative expenses — the overhead costs of running the business, including salaries, marketing, legal fees, and corporate office costs. Excludes COGS and R&D.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | May 25, 2025 | $44.05M | Aug 7, 2025 |
| FY2025 | May 26, 2024 | $40.46M | Aug 7, 2025 |
| FY2024 | May 28, 2023 | $38.97M | Aug 26, 2024 |
| FY2023 | Feb 26, 2023 | $10.28M | Mar 20, 2024 |
| FY2023 | Nov 27, 2022 | $8.29M | Mar 20, 2024 |
| FY2023 | Aug 28, 2022 | $8.10M | Mar 20, 2024 |
| FY2024 | May 29, 2022 | $34.66M | Aug 26, 2024 |
| FY2023 | Feb 27, 2022 | $13.75M | Mar 20, 2024 |
| FY2023 | Nov 28, 2021 | $5.46M | Mar 20, 2024 |
| FY2023 | Aug 29, 2021 | $6.95M | Mar 20, 2024 |
Operating Cash Flow
Cash generated from core business operations — a more reliable measure of financial health than net income because it strips out non-cash items like depreciation and one-time charges.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | May 25, 2025 | ($206.0K) | Aug 7, 2025 |
| FY2025 | May 26, 2024 | $257.0K | Aug 7, 2025 |
| FY2024 | May 28, 2023 | ($17.44M) | Aug 26, 2024 |
| FY2023 | Feb 26, 2023 | ($15.18M) | Mar 20, 2024 |
| FY2023 | Nov 27, 2022 | ($3.45M) | Mar 20, 2024 |
| FY2023 | Aug 28, 2022 | ($1.10M) | Mar 20, 2024 |
| FY2024 | May 29, 2022 | ($22.59M) | Aug 26, 2024 |
| FY2023 | Feb 27, 2022 | ($20.74M) | Mar 20, 2024 |
| FY2023 | Nov 28, 2021 | ($3.43M) | Mar 20, 2024 |
| FY2023 | Aug 29, 2021 | $1.38M | Mar 20, 2024 |
Capital Expenditures (Capex)
Cash spent on acquiring or upgrading physical assets — property, equipment, and infrastructure. High capex businesses include manufacturing, telecom, and energy companies.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | May 25, 2025 | $13.42M | Aug 7, 2025 |
| FY2025 | May 26, 2024 | $18.40M | Aug 7, 2025 |
| FY2022 | May 29, 2022 | $26.23M | Mar 16, 2023 |
| FY2022 | May 30, 2021 | $19.26M | Mar 16, 2023 |
| FY2022 | May 31, 2020 | $12.21M | Mar 16, 2023 |
| FY2021 | May 26, 2019 | $44.73M | Jul 29, 2021 |
| FY2020 | May 27, 2018 | $33.59M | Aug 14, 2020 |
| FY2019 | May 28, 2017 | $23.00M | Aug 1, 2019 |
| FY2018 | May 29, 2016 | $39.70M | Aug 9, 2018 |
| FY2017 | May 31, 2015 | $17.51M | Mar 15, 2018 |
Total Assets
The total value of everything the company owns or controls — cash, investments, receivables, property, equipment, and intangibles. Reported as of fiscal year end.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | May 25, 2025 | $239.34M | Aug 7, 2025 |
| FY2025 | May 26, 2024 | $253.96M | Aug 7, 2025 |
| FY2024 | May 28, 2023 | $253.55M | Aug 26, 2024 |
| FY2023 | Feb 26, 2023 | $236.66M | Mar 20, 2024 |
| FY2023 | Nov 27, 2022 | $275.97M | Mar 20, 2024 |
| FY2023 | Aug 28, 2022 | $266.38M | Mar 20, 2024 |
| FY2023 | May 29, 2022 | $274.70M | Mar 20, 2024 |
| FY2023 | Feb 27, 2022 | $324.24M | Mar 20, 2024 |
| FY2023 | Nov 28, 2021 | $421.31M | Mar 20, 2024 |
| FY2023 | Aug 29, 2021 | $444.73M | Mar 20, 2024 |
Total Liabilities
All financial obligations owed to outside parties — including debt, accounts payable, accrued expenses, and deferred revenue. Subtracting liabilities from total assets gives stockholders' equity.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | May 25, 2025 | $191.91M | Aug 7, 2025 |
| FY2025 | May 26, 2024 | $200.06M | Aug 7, 2025 |
| FY2024 | May 28, 2023 | $218.46M | Aug 26, 2024 |
| FY2023 | Feb 26, 2023 | $163.10M | Mar 20, 2024 |
| FY2023 | Nov 27, 2022 | $204.83M | Mar 20, 2024 |
| FY2023 | Aug 28, 2022 | $188.51M | Mar 20, 2024 |
| FY2023 | May 29, 2022 | $186.88M | Mar 20, 2024 |
| FY2023 | Feb 27, 2022 | $181.68M | Mar 20, 2024 |
| FY2023 | Nov 28, 2021 | $265.88M | Mar 20, 2024 |
| FY2023 | Aug 29, 2021 | $251.61M | Mar 20, 2024 |
Stockholders Equity
The net worth attributable to shareholders: total assets minus total liabilities. Also called book value. Can be negative if liabilities exceed assets, which is common in capital-intensive industries.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | May 25, 2025 | $1.34M | Aug 7, 2025 |
| FY2025 | May 26, 2024 | $11.32M | Aug 7, 2025 |
| FY2025 | May 28, 2023 | ($4.23M) | Aug 7, 2025 |
| FY2023 | Feb 26, 2023 | $35.02M | Mar 20, 2024 |
| FY2023 | Nov 27, 2022 | $71.14M | Mar 20, 2024 |
| FY2023 | Aug 28, 2022 | $77.88M | Mar 20, 2024 |
| FY2024 | May 29, 2022 | $87.82M | Aug 26, 2024 |
| FY2023 | Feb 27, 2022 | $142.56M | Mar 20, 2024 |
| FY2023 | Nov 28, 2021 | $155.42M | Mar 20, 2024 |
| FY2023 | Aug 29, 2021 | $193.12M | Mar 20, 2024 |
Goodwill
An intangible asset representing the premium paid above fair value when acquiring another company. A large goodwill balance signals a history of acquisitions at premium prices.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | May 25, 2025 | $13.88M | Aug 7, 2025 |
| FY2025 | May 26, 2024 | $13.88M | Aug 7, 2025 |
| FY2024 | May 28, 2023 | $13.88M | Aug 26, 2024 |
| FY2023 | Feb 26, 2023 | $13.88M | Mar 20, 2024 |
| FY2023 | Nov 27, 2022 | $13.88M | Mar 20, 2024 |
| FY2023 | Aug 28, 2022 | $13.88M | Mar 20, 2024 |
| FY2023 | May 29, 2022 | $13.88M | Mar 20, 2024 |
| FY2023 | Feb 27, 2022 | $13.88M | Mar 20, 2024 |
| FY2023 | Nov 28, 2021 | $13.88M | Mar 20, 2024 |
| FY2023 | Aug 29, 2021 | $13.88M | Mar 20, 2024 |
Retained Earnings
Cumulative net income kept by the company rather than distributed as dividends. A growing retained earnings balance indicates consistent profitability; a deficit indicates cumulative losses.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | May 25, 2025 | ($205.24M) | Aug 7, 2025 |
| FY2025 | May 26, 2024 | ($166.52M) | Aug 7, 2025 |
| FY2024 | May 28, 2023 | ($178.54M) | Aug 26, 2024 |
| FY2023 | Feb 26, 2023 | ($139.25M) | Mar 20, 2024 |
| FY2023 | Nov 27, 2022 | ($102.75M) | Mar 20, 2024 |
| FY2023 | Aug 28, 2022 | ($89.94M) | Mar 20, 2024 |
| FY2023 | May 29, 2022 | ($78.97M) | Mar 20, 2024 |
| FY2023 | Feb 27, 2022 | ($23.70M) | Mar 20, 2024 |
| FY2023 | Nov 28, 2021 | ($10.12M) | Mar 20, 2024 |
| FY2023 | Aug 29, 2021 | $28.36M | Mar 20, 2024 |
Cash & Equivalents
Highly liquid assets the company holds — cash on hand, bank balances, and short-term investments with maturities of three months or less. A key indicator of short-term financial health.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | May 25, 2025 | $8.27M | Aug 7, 2025 |
| FY2025 | May 26, 2024 | $8.46M | Aug 7, 2025 |
| FY2024 | May 28, 2023 | $19.09M | Aug 26, 2024 |
| FY2023 | Feb 26, 2023 | $2.95M | Mar 20, 2024 |
| FY2023 | Nov 27, 2022 | $5.94M | Mar 20, 2024 |
| FY2023 | Aug 28, 2022 | $2.54M | Mar 20, 2024 |
| FY2023 | May 29, 2022 | $991.0K | Mar 20, 2024 |
| FY2023 | Feb 27, 2022 | $1.10M | Mar 20, 2024 |
| FY2023 | Nov 28, 2021 | $609.0K | Mar 20, 2024 |
| FY2023 | Aug 29, 2021 | $939.0K | Mar 20, 2024 |
Long-Term Debt
Debt obligations due more than one year from the balance sheet date — bonds, term loans, and notes payable. High long-term debt relative to equity can signal elevated financial leverage.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | May 25, 2025 | $130.44M | Aug 7, 2025 |
| FY2025 | May 26, 2024 | $124.67M | Aug 7, 2025 |
| FY2024 | May 28, 2023 | $84.84M | Aug 26, 2024 |
| FY2023 | May 29, 2022 | $98.18M | Mar 20, 2024 |
| FY2022 | May 30, 2021 | $164.90M | Mar 16, 2023 |
| FY2021 | May 31, 2020 | $112.92M | Jul 29, 2021 |
| FY2020 | May 26, 2019 | $96.98M | Aug 14, 2020 |
| FY2019 | May 27, 2018 | $42.30M | Aug 1, 2019 |
| FY2018 | May 28, 2017 | $47.24M | Aug 9, 2018 |
| FY2017 | May 29, 2016 | $53.85M | Mar 15, 2018 |
EPS (Basic)
Net income divided by the weighted average shares outstanding. Basic EPS does not account for dilutive securities like options or convertible bonds — use diluted EPS for a more conservative view.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | May 25, 2025 | (1) | Aug 7, 2025 |
| FY2025 | May 26, 2024 | 0 | Aug 7, 2025 |
| FY2023 | May 28, 2023 | (1) | Mar 20, 2024 |
| FY2023 | Feb 26, 2023 | (1) | Mar 20, 2024 |
| FY2023 | Nov 27, 2022 | 0 | Mar 20, 2024 |
| FY2023 | Aug 28, 2022 | 0 | Mar 20, 2024 |
| FY2023 | May 29, 2022 | (1) | Mar 20, 2024 |
| FY2023 | Feb 27, 2022 | 0 | Mar 20, 2024 |
| FY2023 | Nov 28, 2021 | (1) | Mar 20, 2024 |
| FY2023 | Aug 29, 2021 | 0 | Mar 20, 2024 |
EPS (Diluted)
Net income divided by the fully diluted share count — including all potential shares from options, warrants, and convertible instruments. The more conservative and widely cited EPS figure.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | May 25, 2025 | (1) | Aug 7, 2025 |
| FY2025 | May 26, 2024 | 0 | Aug 7, 2025 |
| FY2023 | May 28, 2023 | (1) | Mar 20, 2024 |
| FY2023 | Feb 26, 2023 | (1) | Mar 20, 2024 |
| FY2023 | Nov 27, 2022 | 0 | Mar 20, 2024 |
| FY2023 | Aug 28, 2022 | 0 | Mar 20, 2024 |
| FY2023 | May 29, 2022 | (1) | Mar 20, 2024 |
| FY2023 | Feb 27, 2022 | 0 | Mar 20, 2024 |
| FY2023 | Nov 28, 2021 | (1) | Mar 20, 2024 |
| FY2023 | Aug 29, 2021 | 0 | Mar 20, 2024 |
Shares Outstanding
Total common shares issued and held by all shareholders, excluding treasury shares. Combined with market price gives market capitalization.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | May 25, 2025 | 37.03M | Aug 7, 2025 |
| FY2025 | May 26, 2024 | 30.56M | Aug 7, 2025 |
| FY2024 | May 28, 2023 | 30.32M | Aug 26, 2024 |
| FY2023 | May 29, 2022 | 29.51M | Mar 20, 2024 |
| FY2022 | May 30, 2021 | 29.33M | Mar 16, 2023 |
| FY2021 | May 31, 2020 | 29.22M | Jul 29, 2021 |
| FY2020 | May 26, 2019 | 29.10M | Aug 14, 2020 |
| FY2019 | May 27, 2018 | 27.70M | Aug 1, 2019 |
| FY2018 | May 28, 2017 | 27.50M | Aug 9, 2018 |
| FY2017 | May 29, 2016 | 27.15M | Mar 15, 2018 |